Inflammatory Breast Cancer (IBC) Research Foundation, Susan G. Komen®, and the Milburn Foundation® have again come together to become a powerful force against inflammatory breast cancer (IBC) – an aggressive subtype of breast cancer that is challenging to diagnose and treat
Earlier this year, IBC Research Foundation and Milburn matched all donations to Komen up to $50,000, and far exceeded their goal to raise $250,000 in funds specifically for research into IBC.
IBC is a particularly aggressive form of breast cancer because it can be missed on a mammogram, doesn’t usually present with a lump, is often misdiagnosed, and spreads quickly. In fact, about 30 percent of those diagnosed with IBC are initially diagnosed with metastatic disease, meaning their cancer has already spread to other parts of the body. Clinical trials for new therapies often either restrict enrollment of IBC patients or combine their outcomes with non-IBC patients, limiting our understanding of this form of breast cancer.
Through this partnership, a focus group of clinicians, researchers and advocates who are experts in the field of IBC convened to identify the most critical questions in IBC and IBC research. Through this patient directed conversation, several vital challenges were identified, including how inflammatory breast cancer is defined in the clinic and for research. The group has developed a set of recommendations to address the challenge of diagnosis, which will be presented at the San Antonio Breast Cancer Symposium in December.
“In our twenty years of IBC research and patient advocacy, we have consistently stressed the need for better definition and diagnostic guidelines for IBC,” said Ginny Mason, Executive Director of the IBC Research Foundation. “We are very pleased that this year’s impressive matching campaign will support continued collaborative work to resolve these long-standing issues, resulting in more timely diagnosis and hopefully saving lives that would have been stolen by IBC.”
“We know treatment options for IBC are lacking, and with few clinical trials focused solely on IBC, there have been few improvements in treatment,” said Paula Schneider, President and CEO of Susan G. Komen. “We must continue to make IBC and metastatic breast cancer a research priority in order to help save the more than 42,000 lives lost each year in the U.S. to metastatic breast cancer. Partnerships like this help us make an even greater impact than we ever could alone.”
“By working hard together, this partnership has amplified the strengths of each organization to bring a potentially significant advancement in IBC to fruition,” said Bryon Davis, President and CEO of the Milburn Foundation. “Our collective work being presented at the San Antonio Breast Cancer Symposium is the first of multiple critical milestones aimed at changing the research landscape in IBC.”
The partnership between the three organizations has now raised more than $2.44 million to date, thanks to earlier matching gift campaigns beginning in 2016. Funds raised have made it possible to invest in breakthrough research, including studies in IBC, aggressive and metastatic breast cancers.
About IBC Research Foundation
Since 1999 the Inflammatory Breast Cancer Research Foundation (IBCRF) has been leading the way in improving the lives of those touched by inflammatory breast cancer (IBC) through the power of action and advocacy. This is accomplished by tenaciously fostering innovative research, creatively educating stakeholders, and tirelessly advocating for both current patients and IBC survivors.
As a web-based non-profit, IBCRF relies on its dedicated volunteers across the country. Guided by the Medical Advisory Board, a group of extraordinary oncology professionals, IBCRF has funded patient-focused IBC research resulting in new discoveries as well as clinical trials. Learn more at www.ibcresearch.org or call 1-877-STOP-IBC. On social media? Join us on Facebook and Twitter (@IBCResearch).
About Susan G. Komen®
Susan G. Komen® is the world’s leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow’s cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social.
About Milburn Foundation
The Milburn Foundation is a private foundation that structures creative strategic partnerships with both public charities and for-profit companies to drive philanthropic innovation for breast cancer research and more. The Milburn Foundation was born out of a father’s love for his daughter when she was diagnosed with Triple Negative Inflammatory Breast Cancer. Milburn is the proud recipient of the 2016 Susan G. Komen Reach Award (for fundraising innovation). Organizations interested in inventive Corporate Social Responsibility (CSR), Venture Philanthropy, Impact Investing or Activist Philanthropy initiatives should contact us to learn more about how our donations can be coupled with a strategic partners’ objectives to amplify impact. Find out more or contact us by visiting TheMilburnFoundation.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005105/en/
Source: Susan G. Komen